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For almost fifty years, improvements in donor 
selection and screening have led to a continuous 
reduction in the risk of transfusion-transmitted hepatitis 
B virus (HBV). However, transmission can still occur 
when blood is collected from hepatitis B surface antigen 
(HBsAg) negative donors during the pre-seroconversion 
window period. Another source of transmission is 
represented by donors with occult HBV infection (OBI), 
a condition characterised by persistent HBV carriage in 
the absence of detectable HBsAg. In many countries, 
this prompted the introduction of nucleic acid testing 
(NAT) for HBV and/or antibodies to hepatitis B core 
(anti-HBc) testing in order to improve detection of 
infectious donations1.
In principle, the implementation of both HBsAg and 
anti-HBc, and HBV NAT provides optimal safety levels as 
it permits the window phase of acute infection, persistent 
occult infection, and HBV variant strains to be detected. 
However, NAT screening is costly, and it is usually beyond 
the budget of low income countries. On the other hand, 
anti-HBc has good sensitivity but very low specificity 
in detecting infectious donations, and therefore its use 
is limited to regions at lower prevalence, where donor 
deferral is sustainable in terms of donation wastage1. 
The residual risk of transfusion transmission of HBV 
varies, therefore, worldwide, being greater in low and 
intermediate income countries, where the prevalence 
of the virus is higher and the implementation anti-HBc 
testing and/or NAT for HBV DNA is not affordable. 
However, the risk might not be negligible even in 
developed countries using HBV DNA but not anti-HBc, 
as the minimal infectious dose of OBI is below the limit 
of detection of current individual NAT assays2.
A few months ago, a group of international experts 
with multidisciplinary backgrounds reviewed the 
existing knowledge of the biology and clinical impact 
of OBI3, providing an update on a landmark paper 
published ten years ago4. It was agreed that transfusion 
transmission of OBI has a global relevance, the impact 
of transmissions is frequently underestimated, and the 
best preventive strategies to improve safety should be 
tailored to local prevalence and available resources.
This issue of the Journal includes two interesting 
contributions to the current debate on HBV screening 
in blood donors. 
The article by Claudio Velati et al.5 describes the 
trends of HBV infection in Italian blood donors over the 
last decade. In Italy, NAT HBV was introduced in 2008, 
while anti-HBc, in order to avoid shortages in the blood 
supply, is not considered mandatory6. The data for this 
study were collected within the Italian Haemovigilance 
System and included an impressive number of donations 
(almost 31 million donations from more than 17 million 
donors), providing solid grounds for risk modelling. 
According to their estimate, the overall residual risk 
of transmitting HBV was less than 1 per 2 million 
donations, i.e., the sum of the risks related to the window 
period (1 per 6 million) and OBI donations (less than 1 
per 4 million). Notably, the risk substantially declined 
during the study period, and was lower in first time 
donors than in repeat donors. As argued by the authors, 
this likely reflects the increasing rate of vaccination 
coverage among young donors. 
Clearly, like any estimate derived from mathematical 
models, these numbers should be taken with some 
caution. As a matter of fact, when the impact of OBI 
was assessed prospectively in European settings where 
anti-HBc was not performed, it was sufficient to examine 
thousands (not millions) of donor/recipient pairs to 
identify various cases of transfusion transmission2,7. 
In the present study, 40% of the units were examined 
by NAT HBV in minipools of 6-24 donations. With 
minipooling, at least 50% of OBI donations cannot be 
identified7, likely leading to some underestimation of 
the risk. In addition, risk modelling was based on the 
optimistic assumption that transfusion transmission 
occurs only from donors who are negative for anti-HBs 
(i.e., less than 10 mIU/L) and that, even in these cases, 
the efficiency of transmission is very low (1.8%). 
However, recent studies indicate that HBV transmission 
can occur at higher rates (up to 37.5%)2,7, and despite 
concomitant detectable anti-HBs in the donor8. 
Finally, and perhaps most importantly, we should 
take into account the fact that anti-HBc screening, 
although not mandatory according to Italian law, was 
voluntarily adopted by many Italian blood centres during 
the period of study. For example, in the nine transfusion 
departments of Lombardy, the most highly populated 
region in Italy, providing 24% of the total Italian blood 
supply, anti-HBc has been in place for the selection of 
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first time donors since 2016. It is impossible to say to 
what extent this has contributed to reducing the overall 
risk of OBI transmission, but we must remember that 
these reassuring Italian data do not necessarily extend to 
other countries where no anti-HBc screening is carried 
out in the blood supply at all.
However, as correctly pointed out by the authors, 
these data testify that the Italian blood supply has now 
reached unprecedented levels of safety. Actually, in their 
article, Velati et al. go well beyond their estimates and 
calculations: they provide a big picture of the successful 
fight against hepatitis B in Italy. This started almost 
30 years ago with universal vaccination of infants and 
children, and continued with extensive campaigns of case 
finding and treatment of carriers, and with the building and 
maintenance of a comprehensive national blood system. 
The article by Diderot Fopa et al.9 is an example 
of co-operation between African, European and 
North American scientists, producing high quality 
epidemiological data. The authors examined more than 
one thousand blood donors in Yaoundé, Cameroon, and 
found a prevalence of HBsAg and anti-HBc reactivity 
of almost 8% and 50%, respectively. Among the 522 
HBsAg negative, anti-HBc positive donors, 6 (0.52% 
of all donations) fulfilled the definition of OBI, which 
means that approximately 1 in 200 blood units released 
for patient transfusions in Cameroon contain HBV 
viraemia and could transmit the infection. These figures 
were not unexpected in an area where HBV is highly 
endemic, confirming that in sub-Saharan Africa these 
OBI donations could have a significant impact10,11. The 
study provides an evidence base for policy decisions. 
Of course, screening based on anti-HBc testing would 
be unfeasible in this area, as it would halve the number 
of donors in an area where the blood supply is already 
insufficient to meet the clinical needs. Implementing 
NAT-based technologies would certainly improve safety; 
alternatively, the introduction of pathogen reduction 
techniques would provide the means to diminish 
infections from multiple pathogens simultaneously, 
including HBV1,3,10. However, as argued by Fopa et al., 
any opportunity to introduce expensive and technically 
demanding procedures in areas with limited logistics 
and staffing resources needs to be carefully balanced. 
For example, the introduction of NAT technologies in 
other sub-Saharan countries a few years ago absorbed a 
high proportion of the total blood service expenditure, 
with an ultimately negative impact on the national 
transfusion system10. In this regard, we fully agree 
with the conclusions of the article by Fopa et al. that 
the African HBV epidemic can only be tackled by 
comprehensive strategies, including vaccination and 
treatment programmes. Blood transfusion centres could 
play an important role in this field, for example, by 
referring HBsAg positive donors (8% in this study) 
for counselling and treatment, and by promoting 
vaccination among donors and their family members. 
On the other hand, these findings support the decision 
to test for anti-HBc immigrants from endemic areas, 
who are likely to remain at higher risk of transmitting 
the infection in affluent countries.
These two studies, with their profoundly different 
risk estimates of HBV infection, are reminders of the 
gap between low- and high-income countries in terms of 
quality and safety of blood supplies. Blood is recognised 
as an essential medicine, but the need for safe blood 
products remains unmet12.
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